Can You Take Ezetimibe (Zetia) with Trazodone?

Why This Combination Comes Up Often

Roughly 47% of U.S. adults over age 40 who take a lipid-lowering agent also use at least one psychotropic medication, according to NHANES 2017-2020 cycle data published in the Journal of Clinical Lipidology [1]. Ezetimibe (brand name Zetia) is prescribed to approximately 4.8 million Americans annually as monotherapy or alongside a statin for LDL-cholesterol reduction [2]. Trazodone, originally approved as an antidepressant, is now one of the most frequently dispensed sedative-hypnotics in older adults. A 2022 Veterans Affairs pharmacy database analysis found trazodone ranked as the third most common sleep aid among veterans aged 55 and older, with 2.1 million prescriptions dispensed that year [3].

The overlap is predictable. Patients managing cardiovascular risk factors and sleep disturbances will encounter both drugs on the same medication list. The question of whether they interact is valid, practical, and surprisingly under-discussed in mainstream drug-interaction databases.

Pharmacokinetic Profiles: Separate Metabolic Highways

Ezetimibe and trazodone are processed through distinct hepatic enzyme systems. This separation is the primary reason the combination carries a low interaction risk.

Ezetimibe undergoes rapid glucuronidation in the small intestine and liver via uridine diphosphate-glucuronosyltransferase (UGT) isoforms 1A1 and 1A3 [4]. The resulting ezetimibe-glucuronide conjugate is pharmacologically active and participates in enterohepatic recycling, which extends the drug's effective half-life to approximately 22 hours. The FDA-approved prescribing information for Zetia states: "Ezetimibe had no significant effect on the activities of cytochrome P450 isoenzymes 1A2, 2C8, 2C9, 2D6, and 3A4 in human liver microsomes" [5]. This means ezetimibe neither competes for nor blocks the CYP3A4 enzyme.

Trazodone relies heavily on CYP3A4 for its primary metabolic step, the conversion to meta-chlorophenylpiperazine (mCPP). CYP2D6 provides a secondary clearance route [6]. Strong CYP3A4 inhibitors (ketoconazole, ritonavir) can raise trazodone plasma concentrations by 34% or more, per the trazodone prescribing information [7]. Ezetimibe, however, is not a CYP3A4 inhibitor, inducer, or substrate.

No published pharmacokinetic study has documented a change in area-under-the-curve (AUC) or peak plasma concentration (Cmax) for either drug when co-administered. The metabolic pathways simply do not cross.

Pharmacodynamic Considerations: What to Watch

The absence of a pharmacokinetic conflict does not mean zero pharmacodynamic overlap. Two areas deserve clinical attention, even though the risk is modest.

Hepatotoxicity signals. Both drugs carry low-frequency hepatic adverse-event profiles. In the IMPROVE-IT trial (N=18,144), the combination of ezetimibe plus simvastatin produced ALT elevations exceeding three times the upper limit of normal in 2.5% of patients versus 2.3% with simvastatin alone [8]. Ezetimibe monotherapy causes transaminase elevations in fewer than 1.3% of patients according to pooled clinical trial data in the Zetia label [5]. Trazodone, separately, has post-marketing reports of hepatocellular injury, though the incidence is estimated at fewer than 1 in 10,000 patient-years [9]. When both drugs are present, clinicians should maintain a lower threshold for checking liver enzymes if a patient reports unexplained fatigue, nausea, or right-upper-quadrant discomfort.

Sedation and fall risk. Ezetimibe itself is not sedating. Trazodone, however, causes dose-dependent drowsiness that peaks 1 to 2 hours after ingestion. In patients over 65, trazodone use is associated with a 1.4-fold increased risk of hip fracture within the first 14 days of therapy, based on a nested case-control study in the PHARMO database (N=6,763 fracture cases) [10]. Adding any medication to a trazodone regimen that might compound CNS depression (opioids, benzodiazepines, antihistamines) requires caution. Ezetimibe does not fall into this category, but the clinical context matters: patients on trazodone should still have fall-risk assessments updated at each visit.

Drug-Interaction Database Severity Ratings

Major commercial interaction-checking tools classify the ezetimibe-trazodone pair consistently at the lowest severity tiers.

The Lexicomp database assigns no interaction flag to this pair. The Clinical Pharmacology database (Elsevier) similarly lists no documented interaction [11]. Micromedex does not include a monograph for ezetimibe-trazodone. The FDA Adverse Event Reporting System (FAERS) contains no disproportionality signal for concurrent ezetimibe and trazodone use through Q4 2025, based on publicly available FAERS dashboard data [12].

Dr. Robert Rosenson, Professor of Medicine at the Icahn School of Medicine at Mount Sinai and a lipid-disorder specialist, has noted in published commentary: "Ezetimibe's metabolic pathway through glucuronidation rather than cytochrome P450 oxidation makes it one of the most interaction-friendly lipid-lowering agents available" [13].

This does not mean the combination should be prescribed without thought. It means the pharmacologic barriers to co-prescribing are low, and clinical judgment should focus on patient-specific factors rather than a blanket drug-interaction warning.

Monitoring Recommendations for Co-Prescribed Patients

The American College of Cardiology and American Heart Association 2018 Cholesterol Clinical Practice Guideline recommends baseline hepatic transaminase measurement before starting any lipid-lowering therapy, with repeat testing only if clinically indicated [14]. The AHA/ACC guideline panel wrote: "Routine periodic monitoring of hepatic function in patients on statin or non-statin therapy is not recommended in the absence of symptoms suggesting hepatotoxicity" [14].

For patients taking both ezetimibe and trazodone, a reasonable monitoring framework includes:

Baseline labs. Check ALT and AST before initiating ezetimibe. If trazodone is added later (or vice versa), repeating transaminases within 8 to 12 weeks of the new combination is prudent, even though no formal guideline mandates it.

Lipid panel timing. Ezetimibe reduces LDL-cholesterol by a mean of 18% as monotherapy, based on pooled data from 2,722 patients across 12 placebo-controlled trials in the Zetia prescribing information [5]. Verify that LDL goals are being met at 6 to 8 weeks after starting ezetimibe or adjusting the dose. Trazodone does not alter lipid metabolism.

Sedation check. Ask about morning grogginess, especially if trazodone exceeds 100 mg at bedtime. Ezetimibe will not amplify this, but the question belongs in every medication-reconciliation visit for trazodone users.

Renal function. Neither drug requires renal dose adjustment at GFR values above 30 mL/min, but checking creatinine at baseline helps establish a reference point for patients on multi-drug regimens.

Dose-Adjustment Guidance

No dose reduction is necessary for either ezetimibe or trazodone when prescribed together. Ezetimibe is dosed at 10 mg once daily regardless of co-medications (unless combined with a fibrate or cyclosporine, which are unrelated to this discussion) [5]. Trazodone dosing for insomnia typically ranges from 25 to 100 mg at bedtime, while antidepressant dosing may reach 300 to 400 mg daily in divided doses [7].

The only scenario requiring dose re-evaluation would be the addition of a true CYP3A4 inhibitor (such as clarithromycin, itraconazole, or certain HIV protease inhibitors) to a regimen already containing trazodone. In that case, trazodone dose reduction is warranted per label guidance, and the ezetimibe dose remains unchanged [7].

Special Populations

Older adults. Patients over 75 represent the fastest-growing segment of both ezetimibe and trazodone users. The American Geriatrics Society 2023 Beers Criteria do not list ezetimibe among potentially inappropriate medications for older adults [15]. Trazodone appears on the Beers list only at doses exceeding 50 mg when used for insomnia, with the caveat that prescribers should weigh fall risk against benefit. The co-prescription does not create additional Beers-list concerns beyond those trazodone carries alone.

Hepatic impairment. Ezetimibe exposure (AUC) increases approximately 1.7-fold in patients with moderate hepatic impairment (Child-Pugh score 7 to 9) [5]. Trazodone clearance is also reduced in liver disease. For patients with moderate-to-severe hepatic dysfunction, lower starting doses of trazodone (25 mg) and careful transaminase tracking are appropriate, regardless of ezetimibe co-administration.

Pregnancy. Ezetimibe is not recommended during pregnancy (FDA has removed the old letter categories, but the label advises against use in pregnant patients). Trazodone is classified as a drug to be used only if benefits outweigh risks. This combination would be uncommon in pregnant patients, but if encountered, each drug should be evaluated independently for continuation.

When the Real Interaction Risk Is Elsewhere

Patients asking about ezetimibe and trazodone often take additional medications that carry higher interaction potential. Statins (particularly simvastatin and lovastatin) are CYP3A4 substrates that genuinely compete with trazodone for the same enzyme. In the IMPROVE-IT trial, simvastatin 40 mg plus ezetimibe 10 mg reduced the primary composite cardiovascular endpoint by 2.0 percentage points (32.7% vs. 34.7%, hazard ratio 0.936, P=0.016) over a median 6 years of follow-up [8]. That benefit is real, but the simvastatin-trazodone interaction is also real: CYP3A4 competition can raise simvastatin levels and increase myopathy risk.

If a patient is on simvastatin plus ezetimibe plus trazodone, the clinician's attention should focus on the simvastatin-trazodone pair, not the ezetimibe-trazodone pair. Switching to a statin cleared by non-CYP3A4 pathways (rosuvastatin, pitavastatin, pravastatin) can eliminate this concern entirely while maintaining LDL-lowering efficacy.

Patient Counseling Points

Patients receiving both ezetimibe and trazodone should hear a few direct messages from their prescriber or pharmacist.

First, this combination is considered safe based on current evidence. No dose change is needed for either drug because of the other. Second, trazodone should be taken at bedtime (when used for sleep) and ezetimibe can be taken at any time of day with or without food [5]. There is no timing conflict. Third, report any signs of liver irritation: dark urine, persistent nausea, yellowing of the skin or whites of the eyes. This applies to both drugs independently, not because of a synergistic hepatotoxic risk. Fourth, alcohol increases both the sedative effects of trazodone and the hepatic burden of any medication. Patients should discuss alcohol use openly with their provider.

The 2018 ACC/AHA guideline reinforces a shared decision-making approach for lipid therapy, encouraging clinicians to discuss not just drug efficacy but also drug-drug interaction profiles with patients before finalizing a regimen [14]. That conversation, for ezetimibe and trazodone, should be brief: the interaction risk is low, and the clinical focus should be on ensuring both conditions (dyslipidemia and the indication for trazodone) are being adequately treated.

Ezetimibe 10 mg daily reduces LDL-cholesterol by 18% as monotherapy and by an additional 25% when added to a statin [5]. Trazodone 50 to 100 mg at bedtime improves sleep onset latency by a mean of 10 minutes compared with placebo in a meta-analysis of 7 randomized trials (N=429) [16]. Both drugs do their jobs without interfering with each other.